New Treatments for Rare Mutations in NSCLC
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
Navigating The Treatment of Schizophrenia Using LAIs In The Time of COVID-19
The rapid onset of COVID-19 in the United States, combined with the dismantling of the spring 2020 medical conference infrastructure and widespread travel bans and social distancing has created a synchronous need in all clinical arenas to manage patients with pre-existing conditions, such as schi
Category
  • Psychiatry
Format
  • Webinar recorded
Credits
  • AANP Contact Hours
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
Best Practices for Using Long-acting Injectable Antipsychotics during COVID-19
​​​​​​Join Drs Les Citrome, Steve Stoner, and Board Certified Family Psychiatric Nurse Practitioner Tory Woodward for this on-demand online activity, as they discuss considerations for implementing LAI clinics and best practices for communicating with patients, caregivers, and clinicians regardin
Category
  • Psychiatry
Format
  • Self-study / Enduring
  • Webinar recorded
Credits
  • AANP Contact Hours
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
Optimizing the Role of the Pharmacist in LAI Administration During COVID-19
In recent years, overwhelming evidence suggests that LAIs may improve adherence, reduce relapse and hospitalizations, lessen the risk of treatment failure, and decrease mortality.
Category
  • Psychiatry
Format
  • Self-study / Enduring
  • Webinar recorded
Credits
  • AANP Contact Hours
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
Applying ADAURA in Practice: Implications for Early Stage EGFRm NSCLC - Medical Moment Two
Medical Moment Two: Expert Insight on Applying the ADAURA Results to Treatment of Early-Stage NSCLC Patients 
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
Applying ADAURA in Practice: Implications for Early Stage EGFRm NSCLC - Medical Moment One
Medical Moment One: Expert Insight on Practical Aspects of Molecular Profiling for Early-Stage NSCLC Cancers 
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
How Do We Identify HER2+ Gastric Cancer?
The implementation of molecular testing, especially analysis of human epidermal growth factor receptor 2 (HER2) status, has had a significant impact on clinical practice and patient care. Join Drs.
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
How Do Antibody-Drug Conjugates (ADCs) Fit into Precision Medicine for Gastric Cancer?
Antibody-drug conjugates or “ADCs” are a novel class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. Nearly 150 investigational ADCs are currently in pre-clinical and clinical trials. Join Drs.
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
What’s the Best Approach to Select Targeted Treatments for HER2+ Gastric Cancer and What are Practical Considerations?
Clinicians must be aware and up-to-date on the most effective approaches to management in order to provide patients with the most appropriate course of therapy. Join Drs.
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
2020 and Beyond: How Immunotherapy is Changing the Game in Bladder Cancer Management
It is estimated that there are >81,000 new cases of metastatic urothelial bladder cancer (mUBC) in the U.S each year, resulting in more than 17,000 bladder cancer specific deaths.
Category
  • Oncology
Format
  • Webinar recorded
Credits
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation

Pages